Astera Labs (ALAB) September Reassessment: Every Metric Passed, the Stock Fell 43% — the Company Didn't Fail the Test, the Market Changed the Exam
Astera Labs passed all seven Q2 checks with zero invalidation triggers, yet the stock is down 43% from its high and fell another 11.5% over four weeks with no news. Peer Credo grew revenue 115% and still lost a third in 30 days; PV Rating A/D is E, RS is 62. Nothing broke — the money left. We test three hypotheses, rebuild the valuation matrix, and add the flow-of-funds axis the August framework was missing.


























































